TWiPO #3 ~ Vincristine Pharmacogenetics, Irinotecan/Temozolomide for Relapsed Neuroblastoma - a podcast by Solving Kids Cancer

April
25, 2011

In this third episode, host Tim Cripe, MD, PhD,
asks his co-hosts to discuss two recent papers that provide new information
about genetic predisposition to increased toxicity to vincristine in some
children, and the results of a phase II study using a combination therapy
(irinotecan and temozolomide) in relapsed or refractory neuroblastoma.

1:24 Maureen
O'Brien, MD discusses "Increased risk of vincristine neurotoxicity
associated with low CYP3A5 expression genotype in children with acute
lymphoblastic leukemia" in Pediatr Blood Cancer. 2011 Mar;56(3):361-7.
doi: 10.1002/pbc.22845. Epub 2010 Nov 11.http://www.ncbi.nlm.nih.gov/pubmed/21225912

22:10 Lars
Wagner, MD discusses "Phase II study of irinotecan and temozolomide in
children with relapsed or refractory neuroblastoma: a Children's Oncology Group
study" from J Clin Oncol. 2011 Jan 10;29(2):208-13. Epub 2010 Nov
29. http://www.ncbi.nlm.nih.gov/pubmed/21115869

Further episodes of This Week in Pediatric Oncology

Further podcasts by Solving Kids' Cancer

Website of Solving Kids' Cancer